Overview

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Status:
Completed
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the impact of a new injection-free six-to-nine month treatment regimen of linezolid, bedaquiline, levofloxacin, pyrazinamide (PZA) and ethionamide/high dose isoniazid (INH) compared to the conventional empiric injection-based regimen. The secondary aim is to determine if other treatment-related outcomes including adverse events, adherence to treatment, culture conversion, and cure/completion are significantly different in the intervention and conventional arms.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Cape Town
Collaborators:
University of Cape Town Lung Institute
University of Limpopo
University of Stellenbosch
Walter Sisulu University
Treatments:
Bedaquiline
Ethionamide
Isoniazid
Kanamycin
Levofloxacin
Linezolid
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ofloxacin
Pyrazinamide